📈 GLP-1s expand beyond weight loss into a broad chronic-disease class
Friedberg's read of a new St. Louis study mining anonymized VA records (1.2M untreated diabetics vs 215k on GLP-1 receptor agonists vs 600k on other diabetes drugs): the GLP-1 cohort shows large hazard-ratio reductions in cardiac arrest (-30%), shock, hepatic failure and respiratory failure, with the only increases in nausea/reflux/musculoskeletal complaints. He argues the mechanism is a gene-expression cascade off the receptor - inflammatory markers off, cellular-repair genes on - not weight loss itself, and that Lilly's phase-2/phase-3 programs across kidney, liver and mental-health indications will confirm it. If so the label and the addressable market expand far past obesity, and demand for the obesity-drug complex keeps compounding.
also touching these tickers, same direction: Retatrutide: Lilly's premium peptide upgrade path 29 (LLY) · Retatrutide: Lilly's premium peptide upgrade path 29 (NVO)
⚖ Why this verdict
fully deterministic — evaluate.py replays this from daily closes; nothing below is editable or hand-set
- Window: 2025-02-07 → 2026-02-07 — first mention + 12-month horizon, then the window locks.
- The call: ▲ LONG LLY (primary play). LLY rose 21.4% over the window → direction-adjusted R = +21.4% (the call made money).
- Benchmark: holding SPY over the same window returned +16.3% → α = +21.4 − (+16.3) = +5.1% — what this call made or lost against just owning the index. This is the number the verdict uses.
- Rule fired:
▶ HIT — R ≥ +10% AND α ≥ +5 ✓ (R 21.4, α 5.1)· PARTIAL — R ≥ +5% OR α ≥ 0· MISS — everything else
- Credit: supporters of a HIT earn 1.0 each, opposers the inverse — this feeds the scoreboard weights. supported: Friedberg | proxy-sensitive: NVO→MISS (-43.4%)
Conviction timeline
bands: green ≥ 65 · watch ≥ 45 · ember ≥ 15
Plays vs SPY · % since first mention (2025-02-07)
Plays
| expression | symbol | kind | relevance | rationale |
|---|---|---|---|---|
| ▲ LONG | LLY | stock | PRIMARY | running the multi-indication trial program Friedberg cites from his Lilly CEO interview |
| ▲ LONG | NVO | stock | adjacent | semaglutide franchise benefits from the same cardiometabolic label expansion |
Mention log
“So this goes to the point, if you guys remember the interview I did a couple months ago with the CEO of Eli Lilly, that they have all these clinical trials going on right now for different indications for the GLP-1 receptor agonists, that they're seeing that there's health benefits beyond just the weight loss in reducing things like kidney disease, obviously liver problems, mental problems and so on.”
“how much do you think really long term when the long term studies are out is going to be that it was the drug or just that being obese is very bad for you?”
Who built this conviction
each voice's total force on the score — supports and opposes from every mention, weighted exactly as the replay applied them · share = % of all mention-driven movement
⏳ decay drained -26.6 over the idea's life — that's time passing, attributed to no one
Score events
| episode | kind | Δ | after | note |
|---|---|---|---|---|
| E214 2025-02-07 | init | +36.4 | 36.4 | E214 born by Friedberg (explicit_prediction x3) [w=0.87] |
| E214 2025-02-07 | oppose | -4.8 | 31.6 | E214 Antonio Gracias opposes x1 [w=0.50] |
| E215 2025-02-15 | decay | -1.3 | 30.3 | E215 silent |
| E216 2025-02-21 | decay | -1.2 | 29.1 | E216 silent |
| E217 2025-03-01 | decay | -1.2 | 28.0 | E217 silent |
| E218 2025-03-08 | decay | -1.1 | 26.8 | E218 silent |
| E219 2025-03-15 | decay | -1.1 | 25.8 | E219 silent |
| E220 2025-03-22 | decay | -1.0 | 24.7 | E220 silent |
| E221 2025-03-29 | decay | -1.0 | 23.7 | E221 silent |
| E222 2025-04-05 | decay | -0.9 | 22.8 | E222 silent |
| E223 2025-04-11 | decay | -0.9 | 21.9 | E223 silent |
| E224 2025-04-19 | decay | -0.9 | 21.0 | E224 silent |
| E225 2025-04-26 | decay | -0.8 | 20.2 | E225 silent |
| E226 2025-05-02 | decay | -0.8 | 19.4 | E226 silent |
| E227 2025-05-09 | decay | -0.8 | 18.6 | E227 silent |
| E228 2025-05-17 | decay | -0.7 | 17.8 | E228 silent |
| E229 2025-05-24 | decay | -0.7 | 17.1 | E229 silent |
| E231 2025-06-13 | decay | -0.7 | 16.4 | E231 silent |
| E232 2025-06-21 | decay | -0.7 | 15.8 | E232 silent |
| E233 2025-06-28 | decay | -0.6 | 15.2 | E233 silent |
| E234 2025-07-04 | decay | -0.6 | 14.5 | E234 silent |
| E235 2025-07-11 | decay | -0.6 | 14.0 | E235 silent |
| E236 2025-07-19 | decay | -0.6 | 13.4 | E236 silent |
| E237 2025-08-01 | decay | -0.5 | 12.9 | E237 silent |
| E238 2025-08-09 | decay | -0.5 | 12.4 | E238 silent |
| E239 2025-08-15 | decay | -0.5 | 11.9 | E239 silent |
| E240 2025-08-22 | decay | -0.5 | 11.4 | E240 silent |
| E241 2025-08-29 | decay | -0.5 | 10.9 | E241 silent |
| E242 2025-09-07 | decay | -0.4 | 10.5 | E242 silent |
| E243 2025-09-19 | decay | -0.4 | 10.1 | E243 silent |
| E244 2025-09-27 | decay | -0.4 | 9.7 | E244 silent |
| E245 2025-10-03 | decay | -0.4 | 9.3 | E245 silent |
| E246 2025-10-10 | decay | -0.4 | 8.9 | E246 silent |
| E247 2025-10-17 | decay | -0.4 | 8.6 | E247 silent |
| E248 2025-10-24 | decay | -0.3 | 8.2 | E248 silent |
| E249 2025-10-31 | decay | -0.3 | 7.9 | E249 silent |
| E250 2025-11-07 | decay | -0.3 | 7.6 | E250 silent |
| E251 2025-11-14 | decay | -0.3 | 7.3 | E251 silent |
| E252 2025-11-22 | decay | -0.3 | 7.0 | E252 silent |
| E253 2025-12-06 | decay | -0.3 | 6.7 | E253 silent |
| E254 2025-12-13 | decay | -0.3 | 6.4 | E254 silent |
| E255 2025-12-19 | decay | -0.3 | 6.2 | E255 silent |
| E256 2025-12-31 | decay | -0.2 | 5.9 | E256 silent |
| E257 2026-01-10 | decay | -0.2 | 5.7 | E257 silent |
| E258 2026-01-17 | decay | -0.2 | 5.5 | E258 silent |
| E259 2026-01-30 | decay | -0.2 | 5.2 | E259 silent |
| E260 2026-02-07 | decay | -0.2 | 5.0 | E260 silent |